Early consolidation by myeloablative radiochemotherapy followed by autologous stem-cell transplantation in first remission significantly prolongs progression-free survival in mantle cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 105 (2005), 2677–2684., , et al.
Oligonucleotide microarrays demonstrate the highest frequency of ATM mutations in the mantle cell subtype of lymphoma. Proc. Natl. Acad. Sci. USA 100 (2003), 5372–5377., , et al.
Pathogenesis of mantle cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways. J. Clin. Oncol. 23 (2005), 6364–6369., , , and
The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared to FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group (GLSG). Blood 104 (2004), 3064–3071., , et al.
Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide and mitoxantrone (R-FCM) in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 108 (2006), 4003–4008., , et al.
Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J. Clin. Oncol. 23 (2005), 705–711., , et al.
Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood 102 (2003), 749–755., , et al.
High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 99 (2002), 3158–3162., , et al.
CDK4 and MDM2 gene alterations mainly occur in highly proliferative and aggressive mantle cell lymphomas with wild-type INK4a/ARF locus. Cancer Res. 65 (2005), 2199–2206., , et al.
Results of a prospective randomised open label phase III study comparing rituximab plus mitoxantrone, chlorambucile, prednisolone chemotherapy (R-MCP) versus MCP alone in untreated advanced indolent non-Hodgkin's lymphoma (NHL) and mantle cell lymphoma (MCL). Blood 104 (2004), abstract 584., , et al.
Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J. Clin. Oncol. 21 (2003), 4407–4412., , et al.
Sequential chemotherapy regimens followed by high-dose therapy with stem-cell transplantation in mantle cell lymphoma: an update of a prospective study. Haematologica 89 (2004), 1275–1276., , . et al.
Immuno-chemotherapy with rituximab and CHOP significantly improves response and time to treatment failure but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). J. Clin. Oncol. 23 (2005), 1984–1992., , et al.
Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 104 (2004), 3535–3542., , et al.
Sequestration of p27Kip1 protein by cyclin D1 in typical and blastic variants of mantle cell lymphoma (MCL): implications for pathogenesis. Blood 101 (2003), 3181–3187., , et al.
High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus Hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J. Clin. Oncol. 23 (2005), 7013–7023., , et al.
PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma. Proc. Natl. Acad. Sci. USA 88 (1991), 9638–9642., , et al.
The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 3 (2003), 185–197., , et al.
From centrocytic to mantle cell lymphoma: a clinicopathologic and molecular review of 3 decades. Human Pathol. 33 (2002), 7–20. and
Checkpoint kinase 1 (CHK1) protein and mRNA expression is downregulated in aggressive variants of human lymphoid neoplasms. Leukemia 19 (2005), 112–117., , et al.
Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma. J. Clin. Oncol. 18 (2000), 773–779., , et al.